Scary tales of The-Next-Big-Social-Thing killing off the first digital marketing blockbuster have been building for years. McKinsey’s November 2013 iConsumer survey reported a 20 percent decline in email usage between 2008 and 2012, as the medium gave up ground to social networks and mobile messaging apps.
Email marketing is still very much with us, despite much talk of its demise. But, writes Peter Houston, it has moved on from its “spammy” adolescence.
Scary tales of The-Next-Big-Social-Thing killing off the first digital marketing blockbuster have been building for years. McKinsey’s November 2013 iConsumer survey reported a 20 percent decline in email usage between 2008 and 2012, as the medium gave up ground to social networks and mobile messaging apps. But email, like so many well established communication channels, just won’t roll over and die.
Peter Houston
Actually, the long-anticipated demise of email marketing looks further away than ever with practitioners using data to make better decisions, developing sophisticated relationships with their customers and leaving email’s spotty, spammy adolescence behind. According to the 2014 Email Marketing Census from eConsultancy, commercial email volumes are growing and email is ranked top for marketing ROI.
Email marketing’s growing maturity is down to its role as the corner-stone of multichannel marketing, a unique identifier at the centre of a 360-degree view of the customer. In the rapidly shifting landscape of social media, it can be the only thing linking together disparate social accounts and applications and unlocking a customer’s multichannel behaviors.
Most people - there are almost 4 billion email accounts globally - are very comfortable with email as a channel for communication. More than 90 percent of US consumers check their email every day. They interact with about 11 brands by email and, given the choice, 90 percent would like to receive commercial updates by email newsletter, compared with just 10 percent for Facebook.
There’s a strong personal aspect to email with people receiving messages directly to their own inbox and often storing messages that are important to them. This and its scalability has made email a cost-effective marketing tool. But it has also led to it being used as something of a blunt instrument and led to many consumers equating email marketing as spam marketing.
Traditional email marketing schedules have centred on a regular promotional blasts, scattergun broadcasts that have gone to everyone, everywhere, all at one time. But smarter, grown-up email marketing strategies, are pushing up ROI by increasing relevancy - sending the right information to the right person at the right time.
Like so much in today’s marketing world, better targeting of email messages relies on data. Increased use of behavioral analysis, a view of content that customers have engaged with, facilitates more relevant and timely email campaigns. And marketers are choreographing the customer journey more carefully to capture demographic and attitudinal information and better target relevant content.
As patients and HCPs increase their online engagement, pharma marketers will discover new opportunities to deliver ever tighter messaging. Email targeting can now be reactive, using marketing automation based on behaviours, but it can also be proactive, building on customer insight developed from the interpretation of data. The best approach is probably a balance of automation and insight.
It’s important to realize, however, that there is more data volume and complexity out there than ever before. Knowing what’s useful and being able to act on it drives the business and it is key to have a top-down approach in the formation of strategy for data-driven marketing.
In the past the only questions marketers asked were how many emails can I send and how many people opened them? Now it’s not just about questioning the performance of campaigns, but about how those campaigns affect the behaviour of a customer. What stage was the customer at in the lifecycle when they engaged with the content? What content should they receive at each stage? How can you build success for the customer, and build a strong relationship?
The secret to uncovering those behaviours is a robust test and learn approach based on a clear understanding of what exactly you’re trying to achieve. As Rick Meyer points out in a blog post asking ‘Why are DTC marketers ignoring email?’, the key to effective email communication is to ensure relevant communication with each patient segment.
I’ve written here before about data only being useful if it is being used to develop actionable insight or better campaigns; too many organizations still capture huge volumes of data without having a clue how it will actually be used. Using your data to help you do grown up email marketing seems like a pretty good starting point.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.